Challenges for the new Cancer Drugs Fund
Lancet Oncol
.
2016 Apr;17(4):416-418.
doi: 10.1016/S1470-2045(16)00100-5.
Epub 2016 Mar 4.
Authors
Peter Littlejohns
1
,
Albert Weale
2
,
Katharina Kieslich
1
,
James Wilson
3
,
Benedict Rumbold
3
,
Catherine Max
4
,
Annette Rid
5
Affiliations
1
Department of Primary Care and Public Health Sciences, King's College London, London WC2R 2LS, UK.
2
Department of Political Sciences, University College London, London, UK.
3
Department of Philosophy, University College London, London, UK.
4
Catherine Max Consulting, London, UK.
5
Department of Social Science, Health & Medicine, King's College London, London WC2R 2LS, UK. Electronic address: annette.rid@kcl.ac.uk.
PMID:
26948924
DOI:
10.1016/S1470-2045(16)00100-5
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Antineoplastic Agents / economics*
Financial Management*
Humans
State Medicine
United Kingdom
Substances
Antineoplastic Agents